The 45% Bottleneck: How Shrinking HCP Access Is Forcing Pharma to Rethink Commercial Readiness Entirely
The core statistic: HCP access dropped from 60% to 45% in 18 months, with half of accessible HCPs restricting engagement to three or fewer companies.
Everyone in commercial pharma is talking about AI copilots and next-best-action engines.
Very few people are talking about the fact that the room those tools are supposed to help you win is disappearing.
The Number Everyone Missed
HCP access has collapsed. Our latest Veeva Pulse data shows HCP access reverting to low pre-pandemic levels, from 60% in 2022 to 45% today. That word reverting matters. It's not a spike or a glitch. It's a structural reset.
This Isn't a Rep Problem
Most commercial leaders see those numbers and reach for the same lever: our reps need to work harder, smarter, sharper.
That's wrong.
They include new health system restrictions that block access or limit meeting frequency, heightened market consolidation, growing diversity and complexity of modern medicines, and increased patient loads.
Health systems are locking doors. Markets are consolidating. Medicines are harder to explain in five minutes. Physicians have less time.
You can't coach your way around that. You have to build differently.
The Squeeze Gets Worse Where It Matters Most
Here's what should worry you most: the bottleneck isn't spread evenly.
It's concentrated exactly where stakes are highest. This varies across specialties and channels, with the hardest-to-reach HCPs in oncology, internal medicine, and psychiatry.
Oncology. Internal medicine. Psychiatry.
Those aren't edge cases. They're the most complex, most competitive, most clinically nuanced conversations in the industry. That's concentration of difficulty exactly where judgment matters most.
Attention Is the New Access
Getting in the room used to be the hard part.
Now it's only half the problem.
According to MM+M citing Veeva, more than 50% of physicians meet with three or fewer companies. Even the ones you can reach are rationing who gets their time.
Every interaction carries real weight now. There's no room for a generic pitch when the physician has already decided this company makes the cut.
In the UK, it's worse. Pharmaphorum reports HCP access sits at 25% due to health system restrictions, consolidation, growing patient loads, and the increasing complexity of modern medicines.
Twenty-five percent. The room is nearly empty.
The Readiness Gap Was Already There
Layer on a second problem.
Commercial teams have always struggled with ramp time and coaching capacity. That gap was survivable when access was abundant. A rep could learn on the job across dozens of touchpoints a month.
Not survivable now. Not when the room only opens three times.
What This Means for Commercial Teams
Access is shrinking. Readiness is slow.
The old model was a volume game. More calls, more reps, more touches, and the message eventually lands. That model assumed the room stayed open.
It doesn't.
The Real Question
If a rep gets three shots with a given oncologist this year instead of thirty, then the quality of judgment inside each conversation becomes everything.
Not the deck. Not the call frequency. Judgment.
What did the rep notice in the first ninety seconds? How did they interpret hesitation instead of bulldozing past it? What they chose to say next, and why.
Most commercial organizations can't see any of that. They know the call happened. They can't tell you what happened inside it.
That's the gap Signal Intelligence is built to address. Not by replacing the rep's judgment, but by making it visible enough to coach, govern, and improve before the room closes for good.
The access numbers aren't rebounding. So the real question isn't how to get more meetings.
It's whether you'd trust what happens in the three you're allowed to keep.
Sources
PharmExec (Q&A with Dan Rizzo, VP Veeva Global Business Consulting), https://www.pharmexec.com/view/hcp-access-drops-connected-field-engagement-dan-rizzo
MM+M (citing Veeva Pulse Field Trends Report), https://www.mmm-online.com/home/channel/the-return-of-rep-access-report-suggests-bounce-back-in-rate-of-pharma-friendly-docs/
pharmaphorum, https://pharmaphorum.com/sales-marketing/evolving-hcp-access-requires-new-connected-approach-build-engagement